WATCH LIVE
timothy sykes logo
RXRX Stock Draws ARK Buying As AI Drug Story Builds Thumbnail
G Google News

RXRX Stock Draws ARK Buying As AI Drug Story Builds

TIM SYKES•UPDATED JUL. 2, 2026, 5:04 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Recursion Pharmaceuticals Inc. stocks have been trading up by 3.81 percent after a pivotal AI-driven drug discovery breakthrough.

Key Takeaways

  • Cathie Wood’s ARK Investment bought 260,000 shares, signaling fresh institutional interest in RXRX trading.
  • Recursion Pharmaceuticals is now highlighted as one of the largest AI‑first drug discovery platforms.
  • The RXRX model leans on high‑throughput biological data generation and machine‑learning drug candidate selection.
  • Big‑pharma collaborations and an internal clinical pipeline support Recursion’s “full‑stack” AI drug discovery approach.
  • Together, these factors are pulling more momentum traders toward RXRX on both daily and intraday timeframes.

Candlestick Chart

Live Update At 17:03:36 EDT: On Thursday, July 02, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 3.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been grinding higher over the past few weeks, not exploding. The daily chart shows Recursion Pharmaceuticals climbing from closes near $3.15 in mid‑June to around $3.80 by 2026/07/02. That’s a steady, controlled uptrend of roughly 20%, the kind of move trend traders like to stalk for continuation.

Intraday, RXRX traded in a tight band between roughly $3.70 and $3.90, with clean five‑minute swings and no violent air pockets. That tells traders there is real liquidity and two‑sided action, not a thin, one‑and‑done spike. Recursion Pharmaceuticals has been holding its gains into the close, another constructive sign for short‑term momentum.

More Breaking News

On the fundamentals, the picture is early‑stage and aggressive. RXRX generated about $74.7M in revenue over the last year, but carries very heavy losses: profit margins around -840% and negative cash flow of roughly $81M just in the latest quarter. At the same time, Recursion Pharmaceuticals holds about $654.5M in cash and short‑term investments, a current ratio of 5.5, and low debt (total debt‑to‑equity near 0.07). For traders, that mix screams “high‑risk growth story with a decent runway,” not a stable cash machine.

Why Traders Are Watching RXRX Momentum Now

The real spark behind RXRX right now is the headline flow. ARK Investment, run by Cathie Wood and known for chasing disruptive tech, just bought 260,000 shares of Recursion Pharmaceuticals. When a high‑profile growth fund steps back into a name like this, traders pay attention. That type of institutional demand often pulls in algorithms, social chatter, and short‑term breakout players looking to ride the follow‑through.

At the same time, the narrative around RXRX is lining up with that buying. Recursion Pharmaceuticals is being cited as one of the largest and best‑known AI‑first drug discovery companies. The core pitch: RXRX runs huge automated labs generating biological data at scale, then feeds that into machine‑learning systems to identify new drug candidates. That “full‑stack” approach, from data to AI models to clinical pipeline, is rare and easy for the market to understand as a big swing on AI in biotech.

Those big‑pharma collaborations matter too. When large drug companies are willing to partner, it validates Recursion Pharmaceuticals’ platform and gives RXRX more shots on goal. Traders see that as potential for milestone payments, future licensing revenue, and—most important—headline catalysts that can move the stock fast.

Put it together, and RXRX sits at the intersection of two hot themes: AI and drug discovery. The chart is quietly up‑trending, ARK is accumulating, and the story fits the kind of momentum narrative that short‑term traders scan for every day. As long as RXRX holds above recent support in the low‑$3s and keeps attracting volume, this remains a name day traders and swing traders will have on their screens.

Conclusion

RXRX is not a safe, steady compounder. Recursion Pharmaceuticals is a speculative AI‑driven biotech burning a lot of cash, with deeply negative margins and meaningful quarterly losses. But it also has more than $650M in cash, minimal leverage, and high‑profile validation as a leading “full‑stack” AI drug discovery platform partnering with major pharma names. That combination helps explain why ARK Investment just grabbed 260,000 RXRX shares and why momentum traders are circling.

For active traders, the key is to respect both sides of the RXRX story. The upside: strong narrative, real institutional interest, and a chart that is gradually building higher lows from about $3.00 to the current $3.70–$3.90 area. The downside: persistent losses and the constant risk that any bad data, delay, or financing headline can knock Recursion Pharmaceuticals sharply lower. In volatile names like this, risk management has to come first; as millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”

This is exactly the type of setup where process matters more than predictions. As Tim Sykes likes to hammer home, “discipline and cutting losses quickly are what keep you in the game long enough to catch the biggest winners.” RXRX fits that mindset perfectly—trade the price action, respect your risk, and treat the AI‑drug story as context, not a guarantee. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”